MiNK Therapeutics (NASDAQ: INKT) director receives RSU grants instead of cash retainers

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

WIINBERG ULF reported acquisition or exercise transactions in this Form 4 filing.

MiNK Therapeutics director Ulf Wiinberg reported stock-based board compensation rather than open-market trading. On June 1, 2026, he received 1,131 shares of Common Stock at $12.38 per share as a grant in lieu of cash retainers, bringing his direct holdings to 22,650 shares.

The filing also shows a prior grant of 1,285 shares on March 2, 2026 at $10.90 per share, with 21,519 shares held directly after that award. In addition, 27,830 shares are held indirectly in an irrevocable trust for the benefit of his family. Footnotes state these restricted stock units vest one month after grant and that the Q1 2026 grant was filed late due to an administrative error.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider WIINBERG ULF

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,131	$12.38	$14K
Grant/Award	Common Stock	1,285	$10.90	$14K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 22,650 shares (Direct, null); Common Stock — 27,830 shares (Indirect, See footnote)

Footnotes (1)

The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

Key Figures

June 1, 2026 grant: 1,131 shares at $12.38 Direct holdings after June 1, 2026: 22,650 shares March 2, 2026 grant: 1,285 shares at $10.90 +2 more

5 metrics

June 1, 2026 grant 1,131 shares at $12.38 Common Stock awarded in lieu of cash retainers

Direct holdings after June 1, 2026 22,650 shares Total Common Stock held directly following latest grant

March 2, 2026 grant 1,285 shares at $10.90 Common Stock award replacing Q1 2026 board cash compensation

Direct holdings after March 2, 2026 21,519 shares Direct Common Stock position after earlier grant

Indirect trust holdings 27,830 shares Common Stock held in irrevocable family trust

Key Terms

restricted stock units, in lieu of cash retainers, irrevocable trust, board and committee compensation, +1 more

5 terms

restricted stock units financial

"The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

in lieu of cash retainers financial

"The RSUs were received in lieu of cash retainers for board and committee compensation."

irrevocable trust financial

"Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

board and committee compensation financial

"The RSUs were received in lieu of cash retainers for board and committee compensation."

administrative error other

"Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIINBERG ULF

(Last)

(First)

(Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		A		1,285	A	$10.9⁽³⁾	21,519	D
Common Stock	06/01/2026		A		1,131	A	$12.38⁽¹⁾	22,650	D
Common Stock								27,830⁽²⁾	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.

3. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

	By: /s/ Melissa Orilall, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did MiNK Therapeutics (INKT) director Ulf Wiinberg report in this Form 4?

He reported stock-based board compensation, not market buying or selling. The filing shows two awards of common stock granted in lieu of cash retainers, plus indirect holdings in a family trust, clarifying his direct and indirect ownership positions in MiNK Therapeutics.

How many MiNK Therapeutics (INKT) shares did Ulf Wiinberg acquire on June 1, 2026?

He acquired 1,131 shares of Common Stock as a grant on June 1, 2026. The shares were awarded at a reference price of $12.38 per share in lieu of cash retainer payments for his board and committee service during that period.

What prior stock award to Ulf Wiinberg does the MiNK Therapeutics (INKT) Form 4 show?

It shows a March 2, 2026 grant of 1,285 common shares at $10.90 per share. This award also represented restricted stock units received instead of cash board and committee retainers, increasing his direct equity-based compensation from MiNK Therapeutics.

How many MiNK Therapeutics (INKT) shares does Ulf Wiinberg hold directly after these grants?

He holds 22,650 shares directly after the June 1, 2026 grant. Following the earlier March 2, 2026 award, his direct holdings stood at 21,519 shares, so the later grant modestly increased his personal share position as reported in the filing.

What indirect MiNK Therapeutics (INKT) holdings are reported for Ulf Wiinberg?

The Form 4 reports 27,830 shares of Common Stock held indirectly in an irrevocable trust for the benefit of his family. This trust position is separate from his directly held shares and is disclosed as indirect ownership with a specific footnote explanation.

Why does the MiNK Therapeutics (INKT) Form 4 mention an administrative error?

A footnote explains that restricted stock units for Q1 2026 board and committee compensation were not filed on time due to an administrative error. The current Form 4 therefore includes information that should have been reported earlier, correcting the delayed disclosure.

How do the RSU grants in the MiNK Therapeutics (INKT) Form 4 vest?

Footnotes state that each restricted stock unit represents one common share and will vest one month after the grant date. This means Wiinberg’s RSU-based board compensation converts into freely held shares shortly after each award is granted by the company.